Key Highlights

  • Longeveron (NASDAQ: LGVN) appoints Marie Washburn as CFO with a $340,000 base salary and 130,000 restricted stock units.
  • Shareholders approve a reverse stock split at a ratio between 1:2 and 1:20, to be determined by the board.
  • The company increases authorized Class A common stock to 175,000,000 shares and expands its incentive plan by 5,000,000 shares.
  • Dr. Arjun Desai joins the board as a Class III director following the annual meeting.

Leadership Transition Underway

Longeveron (NASDAQ: LGVN) has named Marie Washburn as its new chief financial officer, effective July 13, as the clinical‑stage biotech prepares for a pivotal phase in its development. The appointment follows the departure of former CFO Lisa Locklear, who stepped down on July 10 after serving in the role.

Washburn’s Financial Expertise

Washburn, 51, brings more than two decades of experience in pharmaceutical and biotech finance. Prior to joining the CFO team, she held senior finance responsibilities at Longeveron, overseeing corporate financial operations and reporting. Her earlier career includes leadership positions at Fore Biotherapeutics and Axcella Health, where she guided financial strategy for clinical‑stage companies pursuing complex disease targets.

Compensation and Equity Package

Under her new role, Washburn will earn a $340,000 annual base salary and is eligible for a performance‑based cash incentive targeting 45% of her salary. She will also receive 130,000 restricted stock units as part of her equity compensation, aligning her interests with long‑term shareholder value.

Board Expansion and Governance

The company’s board has appointed Dr. Arjun Desai, 45, as a Class III director, filling a vacancy ahead of key clinical readouts. Desai’s compensation will follow the board’s standard structure, and he will enter into an indemnification agreement consistent with other directors.

Shareholder‑Approved Changes

At the July 1 annual meeting, Longeveron shareholders approved multiple corporate actions, including an increase in authorized Class A common stock to 175,000,000 shares. The board also secured approval for a reverse stock split at a ratio between 1:2 and 1:20, with the exact ratio to be determined later.

Incentive Plan Expansion

The company’s 2021 Incentive Award Plan, was amended to add 5,000,000 shares, supporting future equity grants for executives and employees. The updated plan maintains flexibility for performance‑based and time‑vested awards as Longeveron advances its pipeline.

Accounting and Audit Ratification

Shareholders ratified CBIZ CPAs as the independent auditor for fiscal 2026, ensuring continuity in financial reporting. The move follows standard governance practices as the company prepares for potential regulatory milestones.

FAQs

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.